Discover and read the best of Twitter Threads about #uveal
Most recents (3)
Hey everyone, the first-in-human clinical trial of tebentafusp, the HLA-specific fusion protein targeting gp100, is now online @CCR_AACR! Cool mechanistic proof of concept that you can get CD3+ cells into a poorly infiltrated tumor like #uveal #melanoma.
clincancerres.aacrjournals.org/cgi/content/ab…
clincancerres.aacrjournals.org/cgi/content/ab…
A prelim efficacy signal for uveal melanoma in this trial with a dose (50mcg weekly) that is lower than the 68mcg weekly dose later expanded upon and presented at ASCO last year. Fingers crossed for our patients with this rare disease!
(note: I have fCOI with @Immunocore)
(note: I have fCOI with @Immunocore)
Cytokine Release Syndrome: uncommon but potentially serious side effect. Manageable with everyone's growing experience with adoptive T cell therapy. This trial predated the approval of tocilizumab for severe CRS. Hospitalization mandatory for first 3 doses on study.
Hi #medtwitter + new onc fellows! I treat patients with advanced #melanoma, especially rare ones like #uvealmelanoma (UM). This #tweetorial will discuss:
1) Why UM is unique
2) When does(n’t) immunotherapy work for UM
3) Why we prefer clinical trials for advanced UM
1/x
1) Why UM is unique
2) When does(n’t) immunotherapy work for UM
3) Why we prefer clinical trials for advanced UM
1/x
UM affects about 5/million, and about 3-5% of advanced melanomas in the US arise from the uveal tract (iris, ciliary body, choroid). Of these, iris is rarest + least aggressive, so we often call it “choroidal” melanoma.
Get your dilated eye exams, folks!
2/x
Get your dilated eye exams, folks!
2/x
Choroid and cilio-choroid melanomas can be aggressive. ~50% of the largest tumors metastasize; about 20% of medium ones do.
Look at that lack of plateau! Plenty of mets happen late, >5 years out. It's sad but fascinating when immune system controls disease for years, then (🤬)
Look at that lack of plateau! Plenty of mets happen late, >5 years out. It's sad but fascinating when immune system controls disease for years, then (🤬)
1/ Some #melanoma posters and talks I'm excited to learn more about at @ASCO 2018:
#uveal 1 year OS 74% in @Immunocore Ph1b expansion of IMCgp100 (disclosure: I'm on ad board) meetinglibrary.asco.org/record/162309/…
#uveal 1 year OS 74% in @Immunocore Ph1b expansion of IMCgp100 (disclosure: I'm on ad board) meetinglibrary.asco.org/record/162309/…
2/ #uveal modest activity with BET inhibition as monotherapy
meetinglibrary.asco.org/record/158612/…
and
meetinglibrary.asco.org/record/160188/…
meetinglibrary.asco.org/record/158612/…
and
meetinglibrary.asco.org/record/160188/…
3/ #mucosal important Phase 3 of adjuvant platinum-based chemo vs interferon:
meetinglibrary.asco.org/record/162094/…
Cisplatin + temozolomide mPFS 15 mo, mOS 40 mo - not too much worse than the Phase 2 data. Should chemo be standard adjuvant therapy?
meetinglibrary.asco.org/record/162094/…
Cisplatin + temozolomide mPFS 15 mo, mOS 40 mo - not too much worse than the Phase 2 data. Should chemo be standard adjuvant therapy?
